Detail akcie AbbVie Inc online

Business Summary: AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, AbbVie Inc revenues increased 4% to $56.33B. Net income applicable to common stockholders decreased 12% to $4.24B. Revenues reflect United States segment increase of 2% to $40.78B, International segment increase of less than 1% to $11.51B. Net income was offset by pharmaceutical products segment income decrease of 28% to $9.14B. Dividend per share increased from $5.92 to $6.20.